MannKind (MNKD) Projected to Announce Quarterly Earnings on Wednesday

MannKind (NASDAQ:MNKD) is projected to post its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect MannKind to post earnings of ($0.02) per share and revenue of $108.8040 million for the quarter. Parties may visit the the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

MannKind (NASDAQ:MNKD) last released its earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.03). MannKind had a negative net margin of 6.63% and a negative return on equity of 11.21%. The firm had revenue of $90.17 million during the quarter, compared to analyst estimates of $105.38 million. During the same period last year, the business posted $0.04 earnings per share. The firm’s quarterly revenue was up 15.1% on a year-over-year basis. On average, analysts expect MannKind to post $-0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MannKind Price Performance

Shares of MNKD stock opened at $3.91 on Monday. MannKind has a 12-month low of $2.23 and a 12-month high of $6.51. The firm has a market capitalization of $1.21 billion, a price-to-earnings ratio of -55.85 and a beta of 1.12. The firm has a fifty day moving average of $3.90 and a 200-day moving average of $3.82.

Insider Buying and Selling

In other MannKind news, Director Steven B. Binder sold 16,940 shares of the business’s stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $3.29, for a total transaction of $55,732.60. Following the sale, the director owned 808,008 shares of the company’s stock, valued at approximately $2,658,346.32. The trade was a 2.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.60% of the stock is currently owned by insiders.

Institutional Investors Weigh In On MannKind

Several hedge funds and other institutional investors have recently modified their holdings of MNKD. Franklin Resources Inc. increased its stake in shares of MannKind by 1.4% during the 3rd quarter. Franklin Resources Inc. now owns 162,217 shares of the biopharmaceutical company’s stock worth $871,000 after purchasing an additional 2,201 shares during the last quarter. Mariner LLC increased its holdings in shares of MannKind by 1.3% in the 4th quarter. Mariner LLC now owns 209,479 shares of the biopharmaceutical company’s stock worth $1,188,000 after buying an additional 2,777 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its holdings in shares of MannKind by 108.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,636 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 2,927 shares during the last quarter. Royal Bank of Canada increased its stake in MannKind by 2.1% in the fourth quarter. Royal Bank of Canada now owns 206,612 shares of the biopharmaceutical company’s stock valued at $1,170,000 after acquiring an additional 4,200 shares during the last quarter. Finally, Alliancebernstein L.P. grew its holdings in shares of MannKind by 1.7% during the 3rd quarter. Alliancebernstein L.P. now owns 279,091 shares of the biopharmaceutical company’s stock valued at $1,499,000 after purchasing an additional 4,541 shares during the last quarter. Institutional investors own 49.55% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Mizuho reduced their price target on MannKind from $8.00 to $7.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Royal Bank Of Canada boosted their price target on shares of MannKind from $3.50 to $4.75 and gave the stock a “sector perform” rating in a research report on Thursday, May 7th. Wall Street Zen upgraded MannKind from a “sell” rating to a “hold” rating in a report on Sunday, July 5th. Wells Fargo & Company upped their price objective on MannKind from $11.00 to $14.00 and gave the stock an “overweight” rating in a research note on Thursday. Finally, Zacks Research lowered shares of MannKind from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 7th. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, MannKind presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.34.

About MannKind

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF).